|
MediciNova asthma drug fails trial; shares crash
Reuters (Reuters) – Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade. MediciNova, which is testing MN-221 as a … MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News